Your browser is no longer supported. Please, upgrade your browser.
Settings
ADIL Adial Pharmaceuticals, Inc. daily Stock Chart
ADIL [NASD]
Adial Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own3.40% Shs Outstand10.82M Perf Week-8.45%
Market Cap21.10M Forward P/E- EPS next Y-0.67 Insider Trans- Shs Float6.79M Perf Month-14.47%
Income-13.90M PEG- EPS next Q-0.18 Inst Own16.80% Short Float1.79% Perf Quarter-41.09%
Sales- P/S- EPS this Y48.50% Inst Trans383.76% Short Ratio0.98 Perf Half Y-3.94%
Book/sh1.42 P/B1.37 EPS next Y23.90% ROA-251.10% Target Price5.50 Perf Year-
Cash/sh1.05 P/C1.85 EPS next 5Y- ROE-281.40% 52W Range1.11 - 9.44 Perf YTD-61.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.34% Beta-
Dividend %- Quick Ratio36.60 Sales past 5Y- Gross Margin- 52W Low76.39% ATR0.19
Employees3 Current Ratio36.60 Sales Q/Q- Oper. Margin- RSI (14)39.97 Volatility9.61% 8.61%
OptionableNo Debt/Eq0.00 EPS Q/Q-461.00% Profit Margin- Rel Volume0.35 Prev Close2.06
ShortableYes LT Debt/Eq0.00 EarningsMar 27 Payout- Avg Volume123.75K Price1.95
Recom2.00 SMA20-6.11% SMA50-20.96% SMA200-40.18% Volume43,204 Change-5.34%
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Jun-13-19 09:35AM  Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder ACCESSWIRE +7.29%
Jun-06-19 09:00AM  Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization ACCESSWIRE +6.77%
May-07-19 09:00AM  Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder ACCESSWIRE
Apr-30-19 09:00AM  Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City ACCESSWIRE
Apr-29-19 11:56AM  Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year? Simply Wall St.
Apr-22-19 09:00AM  Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate ACCESSWIRE
Apr-11-19 09:00AM  Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy ACCESSWIRE
Apr-04-19 09:00AM  Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award ACCESSWIRE
Apr-03-19 09:00AM  Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. ACCESSWIRE
Mar-26-19 09:00AM  Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer ACCESSWIRE
Mar-25-19 08:00AM  Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants ACCESSWIRE
Feb-28-19 03:02PM  Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner Benzinga
09:15AM  Adial Pharmaceuticals Featured on CBS in San Francisco GlobeNewswire
Feb-26-19 08:00AM  Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters Over-Allotment Option GlobeNewswire -7.05%
Feb-21-19 01:35PM  Four Biotech Stocks Setting The Standard On Thursday (2/21/19) ACCESSWIRE +17.80%
08:45AM  Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering GlobeNewswire
Feb-20-19 09:00AM  Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adials AD04 for its Phase 3 Trial GlobeNewswire -6.13%
Feb-15-19 08:30AM  Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse GlobeNewswire
Feb-12-19 09:33AM  Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -9.71%
Feb-07-19 09:15AM  Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award GlobeNewswire
Feb-01-19 09:20AM  Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder GlobeNewswire +25.78%
Jan-24-19 08:30AM  Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants GlobeNewswire +10.19%
Jan-23-19 01:57PM  What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)? Simply Wall St. -6.90%
Jan-17-19 09:00AM  Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -6.58%
Jan-15-19 09:05AM  Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series GlobeNewswire +14.58%
Jan-10-19 08:00AM  Adial Pharmaceuticals to Present at The 2019 Wall Street Conference GlobeNewswire +12.07%
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE -8.40%
Dec-26-18 04:18PM  Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today InvestorPlace +27.47%
11:57AM  4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018 ACCESSWIRE
07:30AM  Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 08:00AM  Adial Pharmaceuticals Retires All Outstanding Debt GlobeNewswire +15.12%
07:30AM  Biotech Breakout Candidates ACCESSWIRE
Dec-20-18 06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE -15.66%
Dec-19-18 09:00AM  Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group GlobeNewswire +23.39%
Dec-14-18 06:55AM  Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics ACCESSWIRE -8.65%
Dec-13-18 12:49PM  Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today InvestorPlace +104.93%
08:00AM  Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl GlobeNewswire
Dec-10-18 08:00AM  Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire -10.50%
Dec-04-18 06:45AM  Adial Pharmaceuticals, Analysts Coverage, Review and Target ACCESSWIRE
Nov-29-18 10:10AM  Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma ACCESSWIRE +112.12%
09:10AM  Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder GlobeNewswire
Nov-21-18 08:00AM  Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder GlobeNewswire +12.59%
07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-19-18 08:00AM  Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire
Nov-14-18 08:00AM  Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018 GlobeNewswire
Nov-08-18 09:20AM  Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder GlobeNewswire
Oct-23-18 08:00AM  Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire +7.88%
Sep-26-18 02:15PM  Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City ACCESSWIRE
Sep-18-18 07:30AM  Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent GlobeNewswire +9.59%
Sep-12-18 09:00AM  Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results GlobeNewswire
Sep-04-18 08:00AM  Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern GlobeNewswire
Aug-27-18 09:00AM  Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49 GlobeNewswire -7.08%
Aug-15-18 08:00AM  Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development GlobeNewswire
Aug-02-18 05:31PM  Dawson James Securities Announces the Closing of Initial Public Offering of Adial Pharmaceuticals, Inc. GlobeNewswire -5.96%
Jul-31-18 04:05PM  Adial Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Jul-27-18 07:00AM  Adial Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.